Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

Shattuck Labs Appoints Casi DeYoung as Chief Business Officer

Shattuck Labs, Inc. ("Shattuck"), a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARCtm) platform to develop a novel class of biologic medicines for the treatment of cancer and other diseases, today announced Casi DeYoung has joined the Company as Chief Business Officer.

"We are very pleased to have Casi join our leadership team. As Shattuck continues to advance our potentially transformative therapeutic approach for the treatment of cancer and other diseases, her demonstrated leadership in driving strategic transactions, building organizations, and advancing innovation will be instrumental in achieving our mission of improving the lives of patients," said Josiah Hornblower, Chairman and Chief Executive Officer of Shattuck.

"It is an exciting time to join Shattuck. The ongoing Phase 1 trial of SL-279252 and continued advancement of the ARCtm platform further establish the Company as a leader in the development of novel bi-functional fusion protein therapies," said Ms. DeYoung. "Shattuck has an expansive pipeline of exciting opportunities across multiple therapeutic areas, which makes us uniquely positioned to transform numerous treatment landscapes. I look forward to working with the executive team to continue to build a world-class drug discovery and development company."

Ms. DeYoung joins Shattuck from ImmuneSensor Therapeutics, where she was the Chief Operating Officer responsible for corporate strategy, start-up operations, intellectual property, oversight of the Company's first IND filing and the initiation of a first-in-human Phase 1 clinical trial. Previously, she held several senior leadership positions, including Chief Business Officer at Mirna Therapeutics, Vice President of Business Development at Reata Pharmaceuticals, Vice President of Business Development at ODC Therapy and Operations Director for Oncology at EMD Pharmaceuticals and Merck KGaA. Ms. DeYoung earned a B.S. in Chemistry, from Southwestern University and an M.B.A. from the McCombs School of Business at the University of Texas at Austin.

About Shattuck Labs, Inc.

Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARCtm) platform to develop a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and other diseases. Using its ARCtm platform, Shattuck is building a pipeline of therapeutics, that consolidate checkpoint blockade and TNF receptor agonists into single therapeutics to improve outcomes for patients. Shattuck has offices in Austin, Texas and Durham, North Carolina. For more information, please visit: http://www.shattucklabs.com.

These press releases may also interest you

at 23:22
Hawkeye Systems, Inc. is pleased to announce the creation of a strong body cam platform for biosurveillance and real-time monitoring of issues such as the Coronavirus "It's the personnel at the front line that are likely to be exposed first so our...

at 22:20
LLamasoft, a global leader in enterprise decision solutions announced today the release of its new llama.ai platform. Delivered via a software-as-a-service, llama.ai provides an AI-powered enterprise-scale decision platform that combines deep...

at 22:00
Capsule Technologies, a leading global provider of medical device integration, clinical surveillance, and patient monitoring for hospitals and healthcare organizations, announced today it opened a new office in Dubai's Jebel Ali Free Zone expanding...

at 22:00
ComplyAdvantage, the regtech company transforming the compliance industry through data science and Machine learning to neutralize the risk of financial crimes, today released the '2020 Global Compliance Report.' From regtech innovation to the ever...

at 21:45
EBizCharge, an integrated payment solution developed by leading provider Century Business Solutions, has been recognized as an Acumatica Certified Application (ACA) for Acumatica ERP 2019 R2. Acumatica, a comprehensive, browser-based cloud ERP...

at 21:00
SOPHOLA, Inc. (HQ: Nagano City, Nagano, CEO: Masaki Iino, Short Name: "SOPHOLA") and Primal (HQ: Bangkok, Thailand, Managing Director: Mark McDowell, Short Name: "Primal") are delighted to announce that they today entered into an agreement to bring...

News published on 9 december 2019 at 08:35 and distributed by: